Last reviewed · How we verify
Glucocorticoid combination therapy
Glucocorticoid combination therapy suppresses immune and inflammatory responses by binding to glucocorticoid receptors and modulating cytokine production and immune cell activation.
Glucocorticoid combination therapy suppresses immune and inflammatory responses by binding to glucocorticoid receptors and modulating cytokine production and immune cell activation. Used for Inflammatory and autoimmune diseases (specific indications not detailed in available information).
At a glance
| Generic name | Glucocorticoid combination therapy |
|---|---|
| Also known as | Hydrocortisone, vitamin C and vitamin B1, Dexamethasone, Hydrocortisone |
| Sponsor | Southeast University, China |
| Drug class | Glucocorticoid combination |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Inflammatory diseases |
| Phase | FDA-approved |
Mechanism of action
Glucocorticoids work by translocating to the nucleus and modulating gene expression of pro-inflammatory mediators, reducing production of cytokines like TNF-α, IL-6, and IL-8. The combination approach typically pairs glucocorticoids with other immunosuppressive or anti-inflammatory agents to enhance efficacy while potentially reducing steroid burden and adverse effects.
Approved indications
- Inflammatory and autoimmune diseases (specific indications not detailed in available information)
Common side effects
- Immunosuppression / increased infection risk
- Hyperglycemia
- Osteoporosis
- Hypertension
- Mood disturbances
Key clinical trials
- Twice Weekly Steroids and Exercise as Therapy for DMD (PHASE2)
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis (PHASE4)
- A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer (PHASE2)
- A Study With Imlifidase in Anti-GBM Disease (PHASE3)
- A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome (NA)
- Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) (PHASE2)
- AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucocorticoid combination therapy CI brief — competitive landscape report
- Glucocorticoid combination therapy updates RSS · CI watch RSS
- Southeast University, China portfolio CI